Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2021
Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learningSoufiane M C Mourragui, Marco Loog, Daniel J Vis, et al.
Cell Research|May 26, 2018
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer modelsZheng Xue, Daniel J Vis, Alejandra Bruna, et al.
Genome Medicine|March 21, 2025
Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implicationsDaniel J Vis, Sander A L Palit, Marie Corradi, et al.
Clinical Genitourinary Cancer|January 10, 2017
Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line StudiesSamer Salah, Jae-Lyun Lee, Antonio Rozzi, et al.
Cell Reports. Medicine|August 21, 2024
A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population levelDaniel J Vis, Patricia Jaaks, Nanne Aben, et al.
EMBO Molecular Medicine|June 25, 2015
Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenograftsKristel Kemper, Oscar Krijgsman, Paulien Cornelissen-Steijger, et al.
Nature Communications|March 22, 2024
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitorsAlberto Gil-Jimenez, Nick van Dijk, Joris L Vos, et al.
The EMBO Journal|November 5, 2015
Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugsRosa Planells-Cases, Darius Lutter, Charlotte Guyader, et al.
JCO Precision Oncology|September 11, 2020
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIALJulia D Wulfkuhle, Christina Yau, Denise M Wolf, et al.
Frontiers in Immunology|January 6, 2022
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial CancerNick van Dijk, Alberto Gil-Jimenez, Karina Silina, et al.
Pageof 4